The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
PSA and beyond: alternative prostate cancer biomarkers
Open accessAbstract
BACKGROUND: The use of biomarkers for prostate cancer screening, diagnosis and prognosis has the potential to improve the clinical management of the patients. Owing to inherent limitations of the biomarker prostate-specific antigen (PSA), intensive efforts are currently directed towards a search for alternative prostate cancer biomarkers, particularly those that can predict disease aggressiveness and drive better treatment decisions. METHODS: A literature search of Medline articles focused on recent and emerging advances in prostate cancer biomarkers was performed. The most promising biomarkers that have the potential to meet the unmet clinical needs in prostate cancer patient management and/or that are clinically implemented were selected. CONCLUSIONS: With the advent of advanced genomic and proteomic technologies, we have in recent years seen an enormous spurt in prostate cancer biomarker research with several promising alternative biomarkers being discovered that show an improved sensitivity and specificity over PSA. The new generation of biomarkers can be tested via serum, urine, or tissue-based assays that have either received regulatory approval by the US Food and Drug Administration or are available as Clinical Laboratory Improvement Amendments-based laboratory developed tests. Additional emerging novel biomarkers for prostate cancer, including circulating tumor cells, microRNAs and exosomes, are still in their infancy. Together, these biomarkers provide actionable guidance for prostate cancer risk assessment, and are expected to lead to an era of personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Exosomes: Extracellular organelles important in intercellular communication
Mathivanan, S., Ji, H., & Simpson, R. J. (2010) · Journal of Proteomics · doi:10.1016/j.jprot.2010.06.006 · Cited by 2,537
The MicroRNA Spectrum in 12 Body Fluids
Weber, J. A., Baxter, D. H., Zhang, S., Huang, D. Y., How Huang, K., Jen Lee, M., Galas, D. J., & Wang, K. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.147405 · Cited by 2,477
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., et al. (2009) · Nature · doi:10.1038/nature07762 · Cited by 2,234
de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182
MicroRNAs in body fluids—the mix of hormones and biomarkers
Cortez, M. A., Bueso-Ramos, C., Ferdin, J., Lopez-Berestein, G., Sood, A. K., & Calin, G. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.76 · Cited by 1,465
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., et al. (1998) · JAMA · doi:10.1001/jama.279.19.1542 · Cited by 1,162
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
Bussemakers, M. J. G., van Bokhoven, A., Verhaegh, G. W. C. T., Smit, F. P., Karthaus, H. F. M., Schalken, J. A., Debruyne, F. M. J., Ru, N., & Isaacs, W. B. (1999) · PubMed · Cited by 1,051
Sawyers, C. L. (2008) · Nature · doi:10.1038/nature06913 · Cited by 983
American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010
Wolf, A. M. D., Wender, R. C., Etzioni, R. B., Thompson, I. M., D'Amico, A. V., Volk, R. J., Brooks, D. D., Dash, C., Guessous, I., Andrews, K., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20066 · Cited by 965
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
Lilja, H., Ulmert, D., & Vickers, A. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2351 · Cited by 921
Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer
Nilsson, J., Skog, J., Nordstrand, A., Baranov, V, Mincheva-Nilsson, L., Breakefield, X. O., & Widmark, A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605058 · Cited by 776
Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy
D'Amico, A. V., Chen, M.-H., Roehl, K. A., & Catalona, W. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032975 · Cited by 740
Changes in circulating microRNA levels associated with prostate cancer
Bryant, R. J., Pawlowski, T., Catto, J. W. F., Marsden, G., Vessella, R. L., Rhees, B., Kuslich, C., Visakorpi, T., & Hamdy, F. C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.595 · Cited by 715
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J. G., Jen, J., Isaacs, W. B., Bova, G. S., & Sidransky, D. (1997) · PubMed · Cited by 700
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
Danila, D. C., Heller, G., Gignac, G. A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E., Lilja, H., Schwartz, L., Larson, S., Fleisher, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1506 · Cited by 665
α-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer
Rubin, M. A. (2002) · JAMA · doi:10.1001/jama.287.13.1662 · Cited by 644
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma
Schaefer, A., Jung, M., Mollenkopf, H., Wagner, I., Stephan, C., Jentzmik, F., Miller, K., Lein, M., Kristiansen, G., & Jung, K. (2010) · International Journal of Cancer · doi:10.1002/ijc.24827 · Cited by 611
DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.
de Kok, J. B., Verhaegh, G. W. C. T., Roelofs, R., Hessels, D., Kiemeney, L. A. L. M., Aalders, T. W., Swinkels, D. W., & Schalken, J. A. (2002) · PubMed · Cited by 607
Xi, Y., Nakajima, G., Gavin, E., Morris, C. G., Kudo, K., Hayashi, K., & Ju, J. (2007) · RNA · doi:10.1261/rna.642907 · Cited by 567
Attard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H. M., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3667 · Cited by 533
An Update of the Gleason Grading System
Epstein, J. I. (2010) · Journal of Urology · doi:10.1016/j.juro.2009.10.046 · Cited by 533
Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker
Hernández, J., & Thompson, I. M. (2004) · Cancer · doi:10.1002/cncr.20480 · Cited by 527
Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
Prensner, J. R., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003180 · Cited by 472
PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome
Deras, I. L., Aubin, S. M. J., Blase, A., Day, J. R., Koo, S., Partin, A. W., Ellis, W. J., Marks, L. S., Fradet, Y., Rittenhouse, H., et al. (2008) · Journal of Urology · doi:10.1016/j.juro.2007.11.038 · Cited by 453
Quantifying the role of PSA screening in the US prostate cancer mortality decline
Etzioni, R., Tsodikov, A., Mariotto, A., Szabo, A., Falcon, S., Wegelin, J., diTommaso, D., Karnofski, K., Gulati, R., Penson, D. F., et al. (2008) · Cancer Causes & Control · doi:10.1007/s10552-007-9083-8 · Cited by 423
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment
Tomlins, S. A., Day, J. R., Lonigro, R. J., Hovelson, D. H., Siddiqui, J., Kunju, L. P., Dunn, R. L., Meyer, S., Hodge, P., Groskopf, J., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.04.039 · Cited by 393
on behalf of the Transatlantic Prostate Group, Cuzick, J., Berney, D. M., Fisher, G., Mesher, D., Møller, H., Reid, J. E., Perry, M., Park, J., Younus, A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.39 · Cited by 364
Leyten, G. H. J. M., Hessels, D., Jannink, S. A., Smit, F. P., de Jong, H., Cornel, E. B., de Reijke, T. M., Vergunst, H., Kil, P., Knipscheer, B. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2012.11.014 · Cited by 352
Cooperberg, M. R., Simko, J. P., Cowan, J. E., Reid, J. E., Djalilvand, A., Bhatnagar, S., Gutin, A., Lanchbury, J. S., Swanson, G. P., Stone, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4396 · Cited by 351
Knezevic, D., Goddard, A. D., Natraj, N., Cherbavaz, D. B., Clark-Langone, K. M., Snable, J., Watson, D., Falzarano, S. M., Magi-Galluzzi, C., Klein, E. A., et al. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-690 · Cited by 339
Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer
Khan, S., Jutzy, J. M. S., Valenzuela, M. M. A., Turay, D., Aspe, J. R., Ashok, A., Mirshahidi, S., Mercola, D., Lilly, M. B., & Wall, N. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046737 · Cited by 331
Krohn, A., Diedler, T., Burkhardt, L., Mayer, P.-S., De Silva, C., Meyer-Kornblum, M., Kötschau, D., Tennstedt, P., Huang, J., Gerhäuser, C., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.04.026 · Cited by 324
Moltzahn, F., Olshen, A. B., Baehner, L., Peek, A., Fong, L., Stöppler, H., Simko, J., Hilton, J. F., Carroll, P., & Blelloch, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1229 · Cited by 322
Metastamir: The Field of Metastasis-Regulatory microRNA Is Spreading
Hurst, D. R., Edmonds, M. D., & Welch, D. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2111 · Cited by 299
Yoshimoto, M., Joshua, A. M., Cunha, I. W., Coudry, R. A., Fonseca, F. P., Ludkovski, O., Zielenska, M., Soares, F. A., & Squire, J. A. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.96 · Cited by 279
Exosomes as Biomarker Treasure Chests for Prostate Cancer
Duijvesz, D., Luider, T., Bangma, C. H., & Jenster, G. (2011) · European Urology · doi:10.1016/j.eururo.2010.12.031 · Cited by 278
Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis
Saini, S., Majid, S., Yamamura, S., Tabatabai, L., Suh, S. O., Shahryari, V., Chen, Y., Deng, G., Tanaka, Y., & Dahiya, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2619 · Cited by 275
Self-citationPSA Screening Among Elderly Men With Limited Life Expectancies
Walter, L. C., Bertenthal, D., Lindquist, K., & Konety, B. R. (2006) · JAMA · doi:10.1001/jama.296.19.2336 · Cited by 262
Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer
Tavoosidana, G., Ronquist, G., Darmanis, S., Yan, J., Carlsson, L., Wu, D., Conze, T., Ek, P., Semjonow, A., Eltze, E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019330108 · Cited by 244
The MicroRNA Profile of Prostate Carcinoma Obtained by Deep Sequencing
Szczyrba, J., Löprich, E., Wach, S., Jung, V., Unteregger, G., Barth, S., Grobholz, R., Wieland, W., Stöhr, R., Hartmann, A., et al. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0443 · Cited by 227
Challenges of Cancer Biomarker Profiling
Bensalah, K., Montorsi, F., & Shariat, S. F. (2007) · European Urology · doi:10.1016/j.eururo.2007.09.036 · Cited by 224
Salami, S. S., Schmidt, F., Laxman, B., Regan, M. M., Rickman, D. S., Scherr, D., Bueti, G., Siddiqui, J., Tomlins, S. A., Wei, J. T., et al. (2013) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.04.001 · Cited by 221
Sircar, K., Yoshimoto, M., Monzon, F. A., Koumakpayi, I. H., Katz, R. L., Khanna, A., Alvarez, K., Chen, G., Darnel, A. D., Aprikian, A. G., et al. (2009) · The Journal of Pathology · doi:10.1002/path.2559 · Cited by 208
Sokoll, L. J., Sanda, M. G., Feng, Z., Kagan, J., Mizrahi, I. A., Broyles, D. L., Partin, A. W., Srivastava, S., Thompson, I. M., Wei, J. T., et al. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0007 · Cited by 202
Jiang, Z., Fanger, G. R., Woda, B. A., Banner, B. F., Algate, P., Dresser, K., Xu, J., & Chu, P. G. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00268-5 · Cited by 198
Biomarker discovery and validation: technologies and integrative approaches
Ilyin, S. E., Belkowski, S. M., & Plata-Salamán, C. R. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.06.005 · Cited by 195
Guazzoni, G., Nava, L., Lazzeri, M., Scattoni, V., Lughezzani, G., Maccagnano, C., Dorigatti, F., Ceriotti, F., Pontillo, M., Bini, V., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.03.052 · Cited by 195
Genomic Predictors of Outcome in Prostate Cancer
Boström, P. J., Bjartell, A. S., Catto, J. W. F., Eggener, S. E., Lilja, H., Loeb, S., Schalken, J., Schlomm, T., & Cooperberg, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.008 · Cited by 187
Freedland, S. J., Gerber, L., Reid, J., Welbourn, W., Tikishvili, E., Park, J., Younus, A., Gutin, A., Sangale, Z., Lanchbury, J. S., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.04.043 · Cited by 184
Challenges in Clinical Prostate Cancer: Role of Imaging
Kelloff, G. J., Choyke, P., & Coffey, D. S. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.09.2579 · Cited by 184
Blume-Jensen, P., Berman, D. M., Rimm, D. L., Shipitsin, M., Putzi, M., Nifong, T. P., Small, C., Choudhury, S., Capela, T., Coupal, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2603 · Cited by 179
Crawford, E. D., Rove, K. O., Trabulsi, E. J., Qian, J., Drewnowska, K. P., Kaminetsky, J. C., Huisman, T. K., Bilowus, M. L., Freedman, S. J., Glover, W. L., et al. (2012) · Journal of Urology · doi:10.1016/j.juro.2012.07.023 · Cited by 175
Biomarkers in prostate cancer: what's new?
Sartori, D. A., & Chan, D. W. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000065 · Cited by 172
Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype
Loberg, R. D., Logothetis, C. J., Keller, E. T., & Pienta, K. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0841 · Cited by 151
Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer
Leinonen, K. A., Saramäki, O. R., Furusato, B., Kimura, T., Takahashi, H., Egawa, S., Suzuki, H., Keiger, K., Hahm, S. H., Isaacs, W. B., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0333-t · Cited by 144
Biomarkers in prostate cancer surveillance and screening: past, present, and future
Cary, C., & Cooperberg, M. R. (2013) · Therapeutic Advances in Urology · doi:10.1177/1756287213495915 · Cited by 129
Rubin, M. A., Bismar, T. A., Andrén, O., Mucci, L. A., Kim, R., Shen, R., Ghosh, D., Wei, J. T., Chinnaiyan, A. M., Adami, H., et al. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0801 · Cited by 125
Clinical use of novel urine and blood based prostate cancer biomarkers: A review
Dijkstra, S., Mulders, P., & Schalken, J. A. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.10.023 · Cited by 123
Lazzeri, M., Haese, A., Abrate, A., TAILLE, A. D. L., Palou, J., McNicholas, T., Giovanni Lughezzani, A., Lista, G., Larcher, A., Bini, V., et al. (2013) · British Journal of Urology · doi:10.1111/bju.12217 · Cited by 112
Schoenborn, J. R., Nelson, P., & Fang, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3606 · Cited by 86
Mitochondria and Cancer: Past, Present, and Future
Verschoor, M. L., Ungard, R. G., Harbottle, A., Jakupciak, J. P., Parr, R. L., & Singh, G. (2013) · BioMed Research International · doi:10.1155/2013/612369 · Cited by 71
Diet, MicroRNAs and Prostate Cancer
Saini, S., Majid, S., & Dahiya, R. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0086-x · Cited by 68
Self-citationCannistraci, A., Pace, A. L. D., Maria, R. D., & Bonci, D. (2014) · BioMed Research International · doi:10.1155/2014/146170 · Cited by 58
Clinical application of circulating tumor cells in breast cancer
Broersen, L. H. A., van Pelt, G. W., Tollenaar, R. A. �. �., & Mesker, W. E. (2013) · Cellular Oncology · doi:10.1007/s13402-013-0160-6 · Cited by 55
MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics
Gordanpour, A., Nam, R. K., Sugar, L., & Seth, A. K. (2012) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2012.3 · Cited by 51
MRI of the prostate: Clinical relevance and emerging applications
Mazaheri, Y., Shukla‐Dave, A., Muellner, A., & Hricak, H. (2011) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22420 · Cited by 47
Molecular pathology and prostate cancer therapeutics: from biology to bedside
Rodrigues, D. N., Butler, L. M., Estelles, D. L., & Bono, J. S. D. (2013) · The Journal of Pathology · doi:10.1002/path.4272 · Cited by 40
Prostate Cancer as a Model System for Genetic Diversity in Tumors
Squire, J. A., Park, P. C., Yoshimoto, M., Alami, J., Williams, J. L., Evans, A. J., & Joshua, A. M. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-387688-1.00007-7 · Cited by 38
Extracellular Vesicles in Prostate Cancer: New Future Clinical Strategies?
Giusti, I., & Dolo, V. (2014) · BioMed Research International · doi:10.1155/2014/561571 · Cited by 27
A new era for castrate resistant prostate cancer: A treatment review and update
Fong, M. K., Hare, R. B., & Jarkowski, A. (2012) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155212437599 · Cited by 23
Bologna, M., & Vicentini, C. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_13 · Cited by 17
Cited by
Altered glycosylation in cancer: A promising target for biomarkers and therapeutics
Thomas, D., Rathinavel, A. K., & Radhakrishnan, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188464 · Cited by 372
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
Crawford, E. D., Heidenreich, A., Lawrentschuk, N., Tombal, B., Pompeo, A. C. L., Mendoza-Valdes, A., Miller, K., Debruyne, F. M. J., & Klotz, L. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0079-0 · Cited by 360
Padhani, A. R., Weinreb, J., Rosenkrantz, A. B., Villeirs, G., Turkbey, B., & Barentsz, J. (2019) · European Urology · doi:10.1016/j.eururo.2018.05.035 · Cited by 288
microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer
Bhagirath, D., Yang, T. L., Bucay, N., Sekhon, K., Majid, S., Shahryari, V., Dahiya, R., Tanaka, Y., & Saini, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2069 · Cited by 274
Self-citationBeyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment
Moradi, A., Srinivasan, S., Clements, J., & Batra, J. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09815-3 · Cited by 114
Metadata
- Authors
- Saini, S.
- Venue
- Cellular Oncology
- Published
- 2016-01-20
- Volume
- 39
- Issue
- 2
- Pages
- 97-106
- ISSN
- 1570-5870 (ISSN-L)
- 2211-3428
- 2211-3436
- OpenAlex
- W2257993785
- Cited by
- 295
- References
- 78
- FWCI
- 21.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.